euroendocrinological effects of lithium and citalopram on the cortisol regulation of patients with major depressio

Not Applicable

• Conditions: F32; F33; Depressive episode; Recurrent depressive disorder

• Registration Number: DRKS00003185
• Lead Sponsor: Klinik für Pschiatrie und PsychotherapieUniversitätsklinikums Carl Gustav Carus an derTechnischen Universität Dresden

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2004-06-30
• Study Start: 2011-07-06
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 62

Inclusion Criteria

diagnosis of a major depression according to DSM-IV, SCID I confirmed; at least 15 points on the Hamilton Rating Scale for Depression (21 item version); indication for a antidepressive pharmacotherapy independently of the study; oral and written informed consent; ability to give informed consent

Exclusion Criteria

manic or hypomanic episode in history (bipolar disorder); psychotropic medication within one wek prior to enrollment (one week wash out if neccessary); 20 mg/d diazepam or an equivalent dosage of another bezodiazepine are allowed prior and during the study; severe medical condition; conditions that contraindications to SSRIs or lithium or to the Dex/CRH test (e.g. severe renal dysfunction, severe cardial dysfunction, dysfunction of glucocorticoid or mineralocorticoid regulation); pregnancy; breast feeding; unsecure contraception; other axis I diagnoses beside the affective disorder; substance dependency

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
area under the curve (AUC) for cortisol and for ACTH comparing AUCs before treatement with AUCs after four weeks of pharmacotherapy

Secondary Outcome Measures

Name	Time	Method
clinical efficacy as assessed by weekly ratings with the psychometric scales HAMD, BDI and CGI